Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10

Breast Cancer Research

Volumn 13, Issue 4, 2011, Pages

  Huijts, Petra E A ^a   van Dongen, Minka ^a   de Goeij, Moniek C M ^a   van Moolenbroek, Adrian J ^a   Blanken, Freek ^a   Vreeswijk, Maaike P G ^a   de Kruijf, Esther M ^a   Mesker, Wilma E ^a   van Zwet, Erik W ^a   Tollenaar, Rob A E M ^a   Smit, Vincent T H B M ^a   van Asperen, Christi J ^a   Devilee, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; FGF10 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; FRS2 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ALLELE; ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER PATIENT; CANCER RISK; CELL CULTURE; CORRELATION ANALYSIS; EPITHELIUM CELL; FEMALE; FIBROBLAST CULTURE; GENE EXPRESSION REGULATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SKIN CELL; SKIN CULTURE; SKIN FIBROBLAST; AGED; CYTOLOGY; FIBROBLAST; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; REFERENCE VALUE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN; STROMA CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; ALLELES; BREAST NEOPLASMS; EPITHELIAL CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 10; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; REFERENCE VALUES; SIGNAL TRANSDUCTION; SKIN; STROMAL CELLS;

EID: 84860404613     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2917     Document Type: Article

References (45)

1. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, et al. SEARCH collaborators Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093. 10.1038/nature05887, 2714974, 17529967, SEARCH collaborators.
2. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Thomas G, Chanock SJ. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007, 39:870-874. 10.1038/ng2075, 17529973.
3. Kawase T, Matsuo K, Suzuki T, Hiraki A, Watanabe M, Iwata H, Tanaka H, Tajima K. FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan. Int J Cancer 2009, 125:1946-1952. 10.1002/ijc.24505, 19582883.
4. Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, Wang Y, Tang J, Wang H, Shen H. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 2008, 29:2341-2346. 10.1093/carcin/bgn235, 18845558.
5. Udler MS, Meyer KB, Pooley KA, Karlins E, Struewing JP, Zhang J, Doody DR, MacArthur S, Tyrer J, Pharoah PD, Luben R, Bernstein L, Kolonel LN, Henderson BE, Le Marchand L, Ursin G, Press MF, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Kang D, Yoo KY, Noh DY, Ahn SH, Ponder BA, Haiman CA, . SEARCH Collaborators FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet 2009, 18:1692-1703. 10.1093/hmg/ddp078, 2733817, 19223389, SEARCH Collaborators.
6. Zheng W, Cai Q, Signorello LB, Long J, Hargreaves MK, Deming SL, Li G, Li C, Cui Y, Blot WJ. Evaluation of 11 breast cancer susceptibility loci in African-American women. Cancer Epidemiol Biomarkers Prev 2009, 18:2761-2764. 10.1158/1055-9965.EPI-09-0624, 2759857, 19789366.
7. Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C, Ponder BA. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008, 6:e108. 10.1371/journal.pbio.0060108, 2365982, 18462018.
8. Sun C, Olopade OI, Di RA. rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genet Cytogenet 2010, 197:193-194. 10.1016/j.cancergencyto.2009.11.006, 2831800, 20193855.
9. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149. 10.1016/j.cytogfr.2005.01.001, 15863030.
10. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010, 125:105-117. 10.1016/j.pharmthera.2009.10.001, 19874848.
11. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129. 10.1038/nrc2780, 20094046.
12. Zhu X, Asa SL, Ezzat S. Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. Am J Pathol 2010, 176:2333-2343. 10.2353/ajpath.2010.091049, 2861098, 20348248.
13. Penault-Llorca F, Bertucci F, Adélaïde J, Parc P, Coulier F, Jacquemier J, Birnbaum D, deLapeyrière O. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 1995, 61:170-176. 10.1002/ijc.2910610205, 7705943.
14. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C, Bignell G, Teague J, Smith R, Stevens C, O'Meara S, Parker A, Tarpey P, Avis T, Barthorpe A, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005, 37:590-592. 10.1038/ng1571, 15908952.
15. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 2001, 46:163-172. 10.1002/1097-0045(20010201)46:2<163::AID-PROS1020>3.0.CO;2-T, 11170144.
16. Luqmani YA, Bansal GS, Mortimer C, Buluwela L, Coombes RC. Expression of FGFR2 BEK and K-SAM mRNA variants in normal and malignant human breast. Eur J Cancer 1996, 32A:518-524.
17. Zhu X, Asa SL, Ezzat S. Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol Endocrinol 2009, 23:1397-1405. 10.1210/me.2009-0071, 2737561, 19497954.
18. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 2011, 125:687-696. 10.1007/s10549-010-0855-6, 20361254.
19. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001, 23:291-299.
20. Court lab HW calculator. , http://www.tufts.edu/~mcourt01/Documents/Court%20lab%20-%20HW%20calculator.xls
21. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 2009, 8:580-588. 10.4161/cc.8.4.7657, 19182515.
22. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, González-Neira A, Benítez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dörk T, Schürmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomäki K, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008, 4:e1000054. 10.1371/journal.pgen.1000054, 2291027, 18437204.
23. Katoh M. Cancer genomics and genetics of FGFR2. Int J Oncol 2008, 33:233-237.
24. Singer CF, Gschwantler-Kaulich D, Fink-Retter A, Haas C, Hudelist G, Czerwenka K, Kubista E. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat 2008, 110:273-281. 10.1007/s10549-007-9725-2, 17899370.
25. Zhang C, Fu L, Fu J, Hu L, Yang H, Rong TH, Li Y, Liu H, Fu SB, Zeng YX, Guan XY. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res 2009, 15:4017-4027. 10.1158/1078-0432.CCR-08-2824, 19509166.
26. Garcia-Maya M, Anderson AA, Kendal CE, Kenny AV, Edwards-Ingram LC, Holladay A, Saffell JL. Ligand concentration is a driver of divergent signaling and pleiotropic cellular responses to FGF. J Cell Physiol 2006, 206:386-393. 10.1002/jcp.20483, 16155940.
27. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337. 10.1038/nature03096, 3050735, 15549095.
28. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401. 10.1038/nrc1877, 16572188.
29. Mailleux AA, Spencer-Dene B, Dillon C, Ndiaye D, Savona-Baron C, Itoh N, Kato S, Dickson C, Thiery JP, Bellusci S. Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. Development 2002, 129:53-60.
30. Parsa S, Ramasamy SK, De Langhe S, Gupte VV, Haigh JJ, Medina D, Bellusci S. Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling. Dev Biol 2008, 317:121-131. 10.1016/j.ydbio.2008.02.014, 18381212.
31. Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesis: new insights into epithelial-stromal interactions. Cancer Cell 2007, 12:495-497. 10.1016/j.ccr.2007.11.021, 18068626.
32. Katoh M, Katoh M. FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26. Int J Oncol 2003, 22:1155-1159.
33. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, Strobbe LJ, Swinkels DW, van Engelenburg KC, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Saez B, Lambea J, Godino J, Polo E, Tres A, Picelli S, Rantala J, Margolin S, Jonsson T, Sigurdsson H, Jonsdottir T, Hrafnkelsson J, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2008, 40:703-706. 10.1038/ng.131, 18438407.
34. Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, Harris AL. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol 1999, 10:707-713. 10.1023/A:1008303614441, 10442194.
35. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I. Identification of novel genes that co-cluster with estrogen receptor α in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006, 13:1109-1120. 10.1677/erc.1.01120, 17158757.
36. Hishikawa Y, Tamaru N, Ejima K, Hayashi T, Koji T. Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Arch Histol Cytol 2004, 67:455-464. 10.1679/aohc.67.455, 15781986.
37. Nomura S, Yoshitomi H, Takano S, Shida T, Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Miyazaki M. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br J Cancer 2008, 99:305-313. 10.1038/sj.bjc.6604473, 2480967, 18594526.
38. Tsunoda S, Sakurai H, Saito Y, Ueno Y, Koizumi K, Saiki I. Massive T-lymphocyte infiltration into the host stroma is essential for fibroblast growth factor-2-promoted growth and metastasis of mammary tumors via neovascular stability. Am J Pathol 2009, 174:671-683. 10.2353/ajpath.2009.080471, 2630574, 19116363.
39. Theodorou V, Boer M, Weigelt B, Jonkers J, van der Valk M, Hilkens J. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene 2004, 23:6047-6055. 10.1038/sj.onc.1207816, 15208658.
40. Sorrell JM, Caplan AI. Fibroblasts: a diverse population at the center of it all. Int Rev Cell Mol Biol 2009, 276:161-214.
41. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 2002, 99:12877-12882. 10.1073/pnas.162488599, 130553, 12297622.
42. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY. Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genet 2006, 2:e119. 10.1371/journal.pgen.0020119, 1523235, 16895450.
43. Nolte SV, Xu W, Rennekampff HO, Rodemann HP. Diversity of fibroblasts: a review on implications for skin tissue engineering. Cells Tissues Organs 2008, 187:165-176. 10.1159/000111805, 18042973.
44. Huang GJ, Shifman S, Valdar W, Johannesson M, Yalcin B, Taylor MS, Taylor JM, Mott R, Flint J. High resolution mapping of expression QTLs in heterogeneous stock mice in multiple tissues. Genome Res 2009, 19:1133-1140. 10.1101/gr.088120.108, 2694476, 19376938.
45. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.